Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296266 | 1.00 | MGAM (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL13751256 | 0.87 | HCAR2 (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1299991 | 0.81 | HCAR2 (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL6965002 | 0.79 | — | — | |
| SCHEMBL2763315 | 0.79 | HCAR2 (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL3135210 | 0.78 | — | — | |
| SCHEMBL4424904 | 0.78 | — | — | |
| SCHEMBL525821 | 0.78 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9912439 | 0.78 | — | — | |
| SCHEMBL9654807 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| EP-3286174-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172425-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| US-7323589-B2 | Intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-01-29 | — | — | US | disclosed |
| US-7148372-B2 | Intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060135808-A1 | Novel intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2006-06-22 | — | — | US | disclosed |
| US-20060106245-A1 | 1,1-bis(alkoxycarbonyl)-omega-tert-amino branched chain alkenes or conjugated polyenes; especially for the synthesis of retinoic acid, vitamin A (retinol), retinal, retinonitrile and etretinate | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2006-05-18 | — | — | US | disclosed |
| US-7009069-B2 | Intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2006-03-07 | — | — | US | disclosed |
| US-20040132796-A1 | Novel intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
| US-6281250-B1 | ANTICARCINOGENIC AGENTS | SOUTHERN RESEARCH INSTITUTE | 2001-08-28 | — | — | US | disclosed |
| WO-1999052846-A2 | RETINYL ETHERS, DERIVATIVES AND ANALOGUES AND INHIBITION OF BREAST CARCINOGENESIS | SOUTHERN RESEARCH INSTITUTE (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132796-A1 | Novel intermediates for use in retinoid synthesis | RXRB, RXRG, RXRA | MGAM 4752/4885GAA 4279/4885SI 4026/4885 |
| US-20060106245-A1 | 1,1-bis(alkoxycarbonyl)-omega-tert-amino branched chain alkenes or conjugated polyenes; especially for the synthesis of retinoic acid, vitamin A (retinol), retinal, retinonitrile and etretinate | RBP1, ALDH1A2, RBP4 | MGAM 4875/4885GAA 4835/4885SI 4715/4885 |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | MGAM 3014/4885GAA 316/4885SI 482/4885 |
| US-20060135808-A1 | Novel intermediates for use in retinoid synthesis | RXRG, RXRB, RXRA | MGAM 4826/4885GAA 4556/4885SI 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.